Syntab has been initiated and seed financed in 2010 by co-founder Dr. Andre Koltermann (former CEO and founder of Direvo Biotech AG and former Executive Vice President at Süd-Chemie AG and Clariant AG), a serial biotech entrepreneur, and Prof. Christian Becker (Head of Institute for Biological Chemistry, University of Vienna), an in-depth connoisseur of peptide chemistry and peptide possibilities.

Syntab Therapeutics has been supported by public funding from the German Ministry of Education and Research (BMBF), later on by the State Northrhine-Westphalia and its EFRE program Life Sciences.NRW.

In recent years, the company attracted a group of experienced biotech investors which have shown their profound belief in the company’s potential.